Development of the "SMA NNE," a short neonatal neurological examination for newborns with spinal muscular atrophy

开发“SMA NNE”,一种针对脊髓性肌萎缩症新生儿的简短新生儿神经系统检查

阅读:2

Abstract

The advent of newborn screening for spinal muscular atrophy (SMA) has highlighted the need for easy, quick, clinical tools to be used in infants with SMA identified in the neonatal period. We propose a new short module developed using items from the Hammersmith Neonatal Neurological Examination (HNNE) and from a module developed for floppy infants, both previously used in newborns with SMA. The new module was developed by identifying and selecting the items that were more often found to have abnormal findings in SMA newborns. The proforma was designed by selecting 13 items and converting them into a format that would facilitate the interpretation of the results. The cohort included 25 infants. Based on HNNE and add-on module results, 13 were classified as asymptomatic, 5 as pauci-symptomatic, and 7 as symptomatic. All symptomatic infants showed abnormalities in posture, tone, tremors, and reflexes, along with reduced antigravity movements and abnormal breathing. Among pauci-symptomatic infants, all had abnormal reflexes, three also had tremors, and one showed mild hypotonia. There was excellent inter-observer reliability assessed using intra-class correlation coefficients with 95% confidence intervals (0.947) and full concordance with the original full-length forms. CONCLUSION: Our findings support the use of the short form in clinical practice, especially when time or resources are limited. It can be used in multiple occasions, allowing to detect the onset of possible signs in asymptomatic infants and to follow their progression. WHAT IS KNOWN: • Newborns with SMA identified by neonatal screening may show clinical signs at diagnosis. • These signs may be subtle and easily missed on standard neonatal examination. WHAT IS NEW: • The new form includes a short examination that can reliably detect initial signs of SMA. • The new examination can be used to detect the onset and the progression of clinical signs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。